Feels like we are close. $RDGL
Is $RDGL flying under the radar?
With Mayo's RadioGel study advancing through the IRB's final review process, important milestones are getting closer. First patient dosing, clinical data, IsoPet revenue growth and PrecisionGel represent multiple potential drivers ahead.
The current share price doesn't tell the whole story. For investors willing to look beyond today's trading, RDGL deserves a closer look. The next chapters could be very interesting.
$RDGL #Biotech #CancerResearch #MicroCap #Investing
2
9
204
smiles retweeted
Please see our website for the latest Business Update on our progress with the Mayo Clinic Human Cancer Trials for @radiogel and more answers to your questions on our Investors Q&A page! $RDGL
vivosinc.com/vivos-inc-busin…
smiles retweeted
Team IsoPet celebrates a record breaking week as 20 pets are scheduled to receive PRnT cancer treatments this week! This milestone reflects growing adoption, commercial momentum and our commitment to giving more pets a new chance in the fight against cancer. $RDGL
smiles retweeted
Thank you to our marketing team. Your work is bringing in more inquiries and turning them into real IsoPet patients, making a meaningful difference in the lives of pets and the families who love them. We will share more progress on the advances we are making with IsoPet as we move forward! $RDGL
Exciting growth for @IsoPetForCancer Organic search traffic surged 114% in 2026, with stronger Google/AI search visibility, record pet owner inquiries, and more animals receiving treatment. Read our latest Business Update here $RDGL
vivosinc.com/isopet-com-repo…
smiles retweeted
It’s encouraging to see Dr. Drygas share this work at ACVS. His IsoPet treatments are helping more pet parents access radiation care without the long trips and repeated visits that external beam treatment often requires. We’re also looking forward to the additional abstracts and publications his clinic has in the works. $RDGL
We are excited to be at ACVS to see Dr. Kevin Drygas presenting his clinical research on Post Operative Precision Radionuclide Brachytherapy! His research has paved the way for IsoPet as an option for pets with cancer who cannot pursue traditional radiation therapy. $RDGL
$RDGL Beaten down stock will have its day. Severely undervalued at the moment.
Lots of upcoming catalysts! $RDGL
$RDGL is getting closer to the point where the story can change quickly.
The Mayo IRB process is in Mayo’s hands and advancing. We've already had a sneak peek at the potential through 200+ animal treatments and human experience from the India studies.
Now comes Mayo, first patient, and U.S. clinical data.
At roughly $0.05/share, the current valuation leaves plenty of room for a major revaluation if the clinical story continues to develop positively.
Just as an illustrative scenario, $0.10, $0.20 or even $0.50 would represent significant appreciation from current levels. Not price targets, just showing what a changing valuation could look like as milestones and data reduce uncertainty. 💹
IRB → First Patient → Clinical Data → Validation → Potential Revaluation
The setup is getting very interesting. 🔥
$RDGL #RadioGel #Biotech #Cancer #Investing
smiles retweeted
$RDGL Mayo supports the RadioGel study and has voted to proceed.
The protocol is finalized with FDA conditions incorporated and is moving toward IRB submission.
IRB submission → IRB approval → study activation → first patient.
Progress.
Vivos is pleased to provide a business update on the continued advancement of its U.S. first-in-human feasibility study of RadioGel®, as the Mayo Clinic clinical process progresses toward IRB submission. $RDGL
vivosinc.com/radiogel-irb-up…
$RDGL, IsoPet, RadioGel, PrecisionGel,India study, all for under 25 mil market cap. Just crazy and short term.
🚀 Exciting breakthrough for veterinary oncology!
New prospective study on IsoPet (Y-90 phosphate hydrogel) shows precision radionuclide therapy after incomplete tumor excision is safe, feasible & well-tolerated in 20 cases.
✅ Zero grade 3+ acute adverse events
✅ No systemic toxicity
✅ 12/20 cases free of local regrowth at follow-up
Targeting residual microscopic disease with high-dose radiation while sparing healthy tissue addresses a major cause of treatment failure. Huge potential to transform post-surgical outcomes in pets—and open significant opportunities in vet cancer care.
$RDGL #VetOncology #IsoPet #RadionuclideTherapy
There's a new version of this post
smiles retweeted
A major milestone for Vivos! @IsoPetForCancer is officially shipping from our APEL facility in Richland, WA! In-house production strengthens supply, quality and scalability while positioning Vivos for continued growth in the U.S. and worldwide. $RDGL
$RDGL Excellent milestones Vivos !
We are pleased to announce two significant operational milestones: the commencement of @IsoPetForCancer shipments from its new in-house U.S. production facility, and the receipt of authorization from AERB of India @RadioGel $RDGL
globenewswire.com/news-relea…
$RDGL Bring on those Mayo Clinic Trials ! Excited to see the results out of Mayo !
$RDGL: The Pieces Are Coming Together 🧩
Big day for Vivos.
Today, the company announced two major operational milestones:
✅first IsoPet shipments from its new U.S. production facility
✅AND AERB authorization to move forward with an international manufacturing center in India.
At the same time, RadioGel is moving toward human clinical trials following FDA IDE approval, with the Mayo Clinic IRB submission now the next major step.
Production. Expansion. Clinical development.
The pieces are starting to come together.
globenewswire.com/news-relea…
$RDGL #Biotech #Oncology #RadioGel #Vivos #Biotechstocks #Cancer #smallcap
$RDGL Human trials soon to start at the Mayo Ckinic.
Human studies begin for hard-to-treat cancers. Treatment invented in Tri-Cities tri-cityherald.com/news/busi…
$RDGL at a sub 30 mil market cap and a successful treatment for over 18 different indications .....When this one is discovered, it will run hard imo.
It’s just a matter of time before this gets national attention. Minimally invasive and highly effective cancer treatment. $RDGL
Breaking for $RDGL
✅New article just dropped
✅RadioGel’s first U.S. human studies starting at Mayo Clinic
✅Huge breakthrough + real hope for patients who need better options
tri-cityherald.com/news/busi…
@RadioGel @VivosIncUSA @PNNLab @MayoClinic @TriCityHerald #smallcapstocks $RDGL
tri-cityherald.com/news/busi…
$RDGL. . Maybe news will get out about this great Cancer treatment. Good Mayo results(that are coming) will get national exposure imo.
Breaking for $RDGL
✅New article just dropped
✅RadioGel’s first U.S. human studies starting at Mayo Clinic
✅Huge breakthrough + real hope for patients who need better options
tri-cityherald.com/news/busi…
@RadioGel @VivosIncUSA @PNNLab @MayoClinic @TriCityHerald #smallcapstocks $RDGL
tri-cityherald.com/news/busi…
smiles retweeted
Vivos Inc. (OTCQB: RDGL) is pleased to report our 2026 second quarter progress and corporate update. The press release is linked on our website at VivosInc.com $RDGL
globenewswire.com/news-relea…
$RDGL Nice to see Brad Weeks buy again. Bring on those human trials at Mayo.
🚨 $RDGL Insider Buying (Form 4 Filed)
Vivos Inc President Brad Weeks just added to his position:
✅ 60,000 shares @ $0.05
✅ 32,000 shares @ $0.05
📊 Now owns 1,471,654 shares
This wasn’t options or compensation
👉 Open market buying at current levels
All while:
🟢 FDA IDE approved
🟢 Mayo Clinic (Jacksonville) involved
🟢 Key catalysts ahead
Insiders are buying.
sec.gov/Archives/edgar/data/…
RDGL #Biotech #Microcap #Stocks















